- Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy
- Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies
- Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls
- The complete results of the study will be produced as sample and data analyses work are completed
- Lexaria is already under way on a second study that examines the efficacy of DehydraTECH-enabled CBD in repeat dosing, and the company anticipates positive outcomes based on the partial results of the first study that were just released
Ongoing clinical studies of the DehydraTECH platform’s ability to render therapeutic drugs into a powder or liquid form that increases their ability to be rapidly absorbed by the body without adverse changes to the original substances have yielded important new findings on the blood pressure and heart disease fronts.
Bioavailability technology innovator Lexaria Bioscience (NASDAQ: LEXX) announced partial results from its human clinical study HYPER-H21-1 on July 29, which is evaluating cannabidiol (“CBD”) processed with DehydraTECH, to determine its potential against hypertension.
The initial results show DehydraTECH-enabled CBD produced a reduction in blood pressure in both male and female volunteers and was most pronounced in comparison against generic CBD controls during the first 10 to 50 minutes after administration, adding to Lexaria’s evidences that DehydraTECH-enabled drugs take effect more rapidly than generic controls, according to the company’s news release (https://ibn.fm/ps9d7).
“We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers,” Lexaria CEO Chris Bunka stated in the news release.
According to the U.S. Centers for Disease Control and Prevention (“CDC”), heart disease is the leading cause of death for men, women and most classifications of people divided by racial and ethnic groups in the United States. One in every four deaths is attributed to heart disease alone, and the costs of related health care, medicines and lost job productivity exceed $200 billion each year (https://ibn.fm/obXUx).
Multiple studies involving people with high, average and below-average levels of blood pressure have shown that lowering blood pressure reduces the risk of heart disease and stroke in all of those categories, which is a basis for prescribing blood-pressure-reducing drugs to the population at large based on risk factors of age and prior heart disease events regardless of periodic blood pressure checkup results (https://ibn.fm/C0y58). Blood pressure drugs and related medications have thereby resulted in a multi-billion-dollar industry.
Lexaria’s partial results show its greatest comparative reduction from baseline was in systolic pressure, but there were also marked reductions in relative diastolic pressure from baseline and relative mean arterial pressure from baseline against the generic CBD controls.
“Other studies of coronary heart disease (‘CHD’) have concluded that ‘lowering systolic pressure by 10 mm Hg or diastolic pressure by 5 mm Hg using any of the main classes of drugs reduced CHD events (fatal and nonfatal) by about a quarter and stroke by about a third, regardless of the presence or absence of vascular disease and of pretreatment BP. Heart failure is also reduced by about 25%,” Lexaria’s news release states.
The company also noted that all of the study’s participants tolerated the DehydraTECH-enabled CBD without any serious adverse events or side effects, while some participants who used the concentration-matched, generic CBD control reported unwanted side effects such as gastrointestinal distress including diarrhea.
Lexaria will provide an update on this study when sample and data analyses work for are complete. The company is optimistic that the partial results reported thus far are predictive of further enhanced efficacy through repeat dosing being analyzed in its second human clinical hypertension study, HYPER-H21-2, which is already under way (https://ibn.fm/j5sG0). A third planned human clinical hypertension study will be conducted this year once the results of HYPER-H21-1 and HYPER-H21-2 are carefully evaluated.
The company also anticipates inflammatory marker assessments may ultimately be applicable to its research in the antiviral therapeutics space for potentially treating COVID-19 and other common pro-inflammatory conditions. Lexaria has already successfully demonstrated DehydraTECH usefulness in that area (https://ibn.fm/N6H6u).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
